Starling Oncology Q2 revenue jumps 35%, loss narrows, and a $75M refinancing replaces convertible debt
Summary
Starling Oncology's Q2 revenue rose 35% to $161M, its loss narrowed, and it refinanced $86M in convertible notes with a $75M term loan, issuing 10M warrants at $8.567.
Key Events · Earnings and Guidance · TOI
-
Revenue Surges 35%
Driven by a 57.6% jump in specialty pharmacy to $98.6M and a 5.3% increase in patient services, Q2 2026 revenue hit $161.3M, up from $119.8M a year ago.
-
Loss Narrows Sharply
Operating loss improved to $4.6M from $11.2M, while net loss fell to $9.8M from $17.0M. For the first half of 2026, operating cash flow turned positive at $9.7M, compared with a $15.2M burn last year.
-
$75M Refinancing Replaces Convertible Debt
On July 1, Starling closed a $75M term loan with Orbimed, repaying the entire $86M 4% convertible note. The new debt floats at SOFR + 5.75% (floor 3%), matures in 2031, and carries a $700M trailing revenue covenant starting December 2027.
-
10M Warrants Issued at $8.567
As part of the refinancing, Deerfield received warrants for 10,025,535 shares at an $8.567 exercise price — 65% above the current $5.19 stock price — creating potential future dilution if shares recover.
Analysis · TOI · Industrial Applications And Services
A strong second quarter saw revenue climb 35% year-over-year to $161.3 million, fueled by a 58% surge in specialty pharmacy sales. The operating loss shrank to $4.6 million from $11.2 million a year ago, and the company generated $9.7 million in operating cash flow during the first half of 2026. More importantly, on July 1 the company closed a $75 million term loan with Orbimed, using the proceeds plus cash on hand to retire the entire $86 million convertible note that carried a 4% coupon and complex derivative liabilities. The new debt carries a floating rate (SOFR + 5.75%, floor 3%) and matures in 2031, removing near-term refinancing risk but adding a $700 million trailing revenue covenant starting December 2027. As part of the refinancing, Starling issued 10 million warrants to Deerfield at an $8.567 strike — well above the current $5.19 stock price — so no immediate dilution, but a potential overhang if shares recover. The quarter shows the business gaining operating leverage, but the refinancing terms signal that capital remains expensive for this micro-cap oncology platform.
At the time of this filing, TOI was trading at $5.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $512.9M. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.